General form of registration statement for all companies including face-amount certificate companies

Revenue - Additional Information (Detail)

v2.4.1.9
Revenue - Additional Information (Detail) (USD $)
12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Aug. 31, 2011
Tranches
Aug. 31, 2009
Dec. 31, 2011
Dec. 31, 2012
Sep. 30, 2010
May 31, 2011
Feb. 28, 2013
Deferred Revenue Arrangement [Line Items]                  
Revenue $ 5,365,054us-gaap_Revenues $ 12,427,292us-gaap_Revenues              
Collaboration agreement, license revenue 473,039us-gaap_LicenseAndServicesRevenue 5,159,425us-gaap_LicenseAndServicesRevenue              
Collaboration agreement, milestone payments 3,184,988us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized 1,128,630us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized              
Research and development services revenue 876,619us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned 3,591,855us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned              
BIO Cluster M4 [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Grant received 116,020us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
/ us-gaap_ProductOrServiceAxis
= pirs_BioClusterM4Member
117,023us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
/ us-gaap_ProductOrServiceAxis
= pirs_BioClusterM4Member
             
Funding rate 40.00%pirs_PercentageOfContributionToFund
/ us-gaap_ProductOrServiceAxis
= pirs_BioClusterM4Member
               
BIO Cluster M4 [Member] | Maximum [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments 1,375,017us-gaap_ContractsReceivableClaimsAndUncertainAmounts
/ us-gaap_ProductOrServiceAxis
= pirs_BioClusterM4Member
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
               
Seventh Research Framework Program (FP7 Agreement) [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Grant received   2,915,559us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
/ us-gaap_ProductOrServiceAxis
= pirs_SeventhResearchFrameworkProgramMember
             
European Union [Member] | Seventh Research Framework Program (FP7 Agreement) [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments     7,260,600us-gaap_ContractsReceivableClaimsAndUncertainAmounts
/ us-gaap_ProductOrServiceAxis
= pirs_SeventhResearchFrameworkProgramMember
/ us-gaap_StatementGeographicalAxis
= us-gaap_EuropeanUnionMember
           
Funding rate     64.00%pirs_PercentageOfContributionToFund
/ us-gaap_ProductOrServiceAxis
= pirs_SeventhResearchFrameworkProgramMember
/ us-gaap_StatementGeographicalAxis
= us-gaap_EuropeanUnionMember
           
Tranches of payments     3pirs_NumberOfTranches
/ us-gaap_ProductOrServiceAxis
= pirs_SeventhResearchFrameworkProgramMember
/ us-gaap_StatementGeographicalAxis
= us-gaap_EuropeanUnionMember
           
Other Arrangement [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Research and development services revenue 0us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
/ us-gaap_TypeOfArrangementAxis
= pirs_OtherArrangementMember
138,091us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
/ us-gaap_TypeOfArrangementAxis
= pirs_OtherArrangementMember
             
Allergan Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments 13,000,000us-gaap_ContractsReceivableClaimsAndUncertainAmounts
/ us-gaap_CounterpartyNameAxis
= pirs_AllerganIncMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
               
Allergan Inc [Member] | Collaborative Arrangement [Member] | Upfront Payment Arrangement [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, license revenue       10,000,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_CounterpartyNameAxis
= pirs_AllerganIncMember
/ us-gaap_DeferredRevenueArrangementTypeAxis
= us-gaap_UpFrontPaymentArrangementMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
         
Sanofi [Member] | Collaborative Arrangement [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, revenue recognized 1,400,000us-gaap_RecognitionOfDeferredRevenue
/ us-gaap_CounterpartyNameAxis
= pirs_SanofiMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
4,200,000us-gaap_RecognitionOfDeferredRevenue
/ us-gaap_CounterpartyNameAxis
= pirs_SanofiMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
             
Collaboration agreement, milestone payments 900,000us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
/ us-gaap_CounterpartyNameAxis
= pirs_SanofiMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
0us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
/ us-gaap_CounterpartyNameAxis
= pirs_SanofiMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
             
Description of factors in determining milestones substantive Factors considered in determining the options were substantive were whether (i) Sanofi could obtain the overall objective of the agreement without exercising any options, (ii) Sanofi was able to obtain value from the initial licenses obtained without exercising any options, (iii) the cost to exercise the options was significant relative to the total upfront payment of $4.9 million for two licenses and four options, and (iv) exercising the option created additional financial commitments for Sanofi or imposed economic penalties on Sanofi.                
Collaborative arrangement, consideration             8,100,000us-gaap_DeferredRevenue
/ us-gaap_CounterpartyNameAxis
= pirs_SanofiMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
   
Sanofi [Member] | Collaborative Arrangement [Member] | Expired Option Agreement [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, revenue recognized         700,000us-gaap_RecognitionOfDeferredRevenue
/ us-gaap_CounterpartyNameAxis
= pirs_SanofiMember
/ us-gaap_TransactionTypeAxis
= pirs_ExpiredOptionAgreementMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
       
Sanofi [Member] | Collaborative Arrangement [Member] | Options Exercised [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, revenue recognized           350,000us-gaap_RecognitionOfDeferredRevenue
/ us-gaap_CounterpartyNameAxis
= pirs_SanofiMember
/ us-gaap_TransactionTypeAxis
= pirs_OptionsExercisedMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
     
Collaborative arrangement, consideration                 350,000us-gaap_DeferredRevenue
/ us-gaap_CounterpartyNameAxis
= pirs_SanofiMember
/ us-gaap_TransactionTypeAxis
= pirs_OptionsExercisedMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
Sanofi [Member] | Collaborative Arrangement [Member] | Options, Exercised Price [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaborative arrangement, consideration                 1,400,000us-gaap_DeferredRevenue
/ us-gaap_CounterpartyNameAxis
= pirs_SanofiMember
/ us-gaap_TransactionTypeAxis
= pirs_OptionsExercisedPriceOneMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
Sanofi [Member] | Collaborative Arrangement [Member] | Maximum [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments             55,900,000us-gaap_ContractsReceivableClaimsAndUncertainAmounts
/ us-gaap_CounterpartyNameAxis
= pirs_SanofiMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
   
Sanofi [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Research Milestones [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments             2,100,000us-gaap_ContractsReceivableClaimsAndUncertainAmounts
/ us-gaap_CounterpartyNameAxis
= pirs_SanofiMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= pirs_ResearchAndDevelopmentMilestonesMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
   
Sanofi [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Development Milestones [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments             32,100,000us-gaap_ContractsReceivableClaimsAndUncertainAmounts
/ us-gaap_CounterpartyNameAxis
= pirs_SanofiMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= pirs_DevelopmentMilestonePaymentsMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
   
Sanofi [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Commercial Milestones [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments             21,800,000us-gaap_ContractsReceivableClaimsAndUncertainAmounts
/ us-gaap_CounterpartyNameAxis
= pirs_SanofiMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= pirs_CommercialMilestonesMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
   
Sanofi [Member] | Collaborative Arrangement [Member] | Licenses [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaborative arrangement, consideration             3,500,000us-gaap_DeferredRevenue
/ us-gaap_CounterpartyNameAxis
= pirs_SanofiMember
/ us-gaap_ProductOrServiceAxis
= pirs_LicensingMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
   
Sanofi [Member] | Collaborative Arrangement [Member] | Options to Acquire Additional Licenses [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaborative arrangement, consideration             1,400,000us-gaap_DeferredRevenue
/ us-gaap_CounterpartyNameAxis
= pirs_SanofiMember
/ us-gaap_ProductOrServiceAxis
= pirs_LicenseOptionMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
   
Sanofi [Member] | Collaborative Arrangement [Member] | Research Services [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Research collaboration agreement, estimated period           2 years      
Collaborative arrangement, consideration             3,200,000us-gaap_DeferredRevenue
/ us-gaap_CounterpartyNameAxis
= pirs_SanofiMember
/ us-gaap_ProductOrServiceAxis
= pirs_ResearchAndDevelopmentServicesMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
   
Sanofi [Member] | Collaborative Arrangement [Member] | Research Services [Member] | Extension Term [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Research collaboration agreement, estimated period           40 months      
Sanofi [Member] | Collaborative Arrangement [Member] | Upfront Payment Arrangement [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, license revenue             4,900,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_CounterpartyNameAxis
= pirs_SanofiMember
/ us-gaap_DeferredRevenueArrangementTypeAxis
= us-gaap_UpFrontPaymentArrangementMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
   
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Research collaboration agreement, estimated period 2 years                
Collaboration agreement, revenue recognized 3,000,000us-gaap_RecognitionOfDeferredRevenue
/ us-gaap_CounterpartyNameAxis
= pirs_DaiichiSankyoIncMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
5,600,000us-gaap_RecognitionOfDeferredRevenue
/ us-gaap_CounterpartyNameAxis
= pirs_DaiichiSankyoIncMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
             
Collaboration agreement, milestone payments 2,300,000us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
/ us-gaap_CounterpartyNameAxis
= pirs_DaiichiSankyoIncMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
1,100,000us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
/ us-gaap_CounterpartyNameAxis
= pirs_DaiichiSankyoIncMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
             
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments               98,700,000us-gaap_ContractsReceivableClaimsAndUncertainAmounts
/ us-gaap_CounterpartyNameAxis
= pirs_DaiichiSankyoIncMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
 
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Research Milestones [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments               2,800,000us-gaap_ContractsReceivableClaimsAndUncertainAmounts
/ us-gaap_CounterpartyNameAxis
= pirs_DaiichiSankyoIncMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= pirs_ResearchAndDevelopmentMilestonesMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
 
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Development Milestones [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments               40,500,000us-gaap_ContractsReceivableClaimsAndUncertainAmounts
/ us-gaap_CounterpartyNameAxis
= pirs_DaiichiSankyoIncMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= pirs_DevelopmentMilestonePaymentsMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
 
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Commercial Milestones [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments               54,500,000us-gaap_ContractsReceivableClaimsAndUncertainAmounts
/ us-gaap_CounterpartyNameAxis
= pirs_DaiichiSankyoIncMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= pirs_CommercialMilestonesMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
 
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Additional Diagnostic Milestones [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, milestone payments               900,000us-gaap_ContractsReceivableClaimsAndUncertainAmounts
/ us-gaap_CounterpartyNameAxis
= pirs_DaiichiSankyoIncMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= pirs_AdditionalMilestonePaymentMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
 
Daiichi Sankyo Inc [Member] | Collaborative Arrangement [Member] | Upfront Payment Arrangement [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration agreement, license revenue               10,100,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_CounterpartyNameAxis
= pirs_DaiichiSankyoIncMember
/ us-gaap_DeferredRevenueArrangementTypeAxis
= us-gaap_UpFrontPaymentArrangementMember
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
 
Collaboration Partner One [Member] | Sales Revenue, Net [Member] | Revenue From Partners [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Revenue 2,981,992us-gaap_Revenues
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueNetMember
/ us-gaap_ConcentrationRiskByTypeAxis
= pirs_RevenueFromPartnersMember
/ us-gaap_CounterpartyNameAxis
= pirs_PartnerOneMember
5,573,441us-gaap_Revenues
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueNetMember
/ us-gaap_ConcentrationRiskByTypeAxis
= pirs_RevenueFromPartnersMember
/ us-gaap_CounterpartyNameAxis
= pirs_PartnerOneMember
             
Collaboration Partner Two [Member] | Sales Revenue, Net [Member] | Revenue From Partners [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Revenue 1,354,861us-gaap_Revenues
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueNetMember
/ us-gaap_ConcentrationRiskByTypeAxis
= pirs_RevenueFromPartnersMember
/ us-gaap_CounterpartyNameAxis
= pirs_PartnerTwoMember
4,168,278us-gaap_Revenues
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueNetMember
/ us-gaap_ConcentrationRiskByTypeAxis
= pirs_RevenueFromPartnersMember
/ us-gaap_CounterpartyNameAxis
= pirs_PartnerTwoMember
             
Government Grant [Member] | Sales Revenue, Net [Member] | Revenue From Partners [Member]                  
Deferred Revenue Arrangement [Line Items]                  
Revenue $ 714,388us-gaap_Revenues
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueNetMember
/ us-gaap_ConcentrationRiskByTypeAxis
= pirs_RevenueFromPartnersMember
/ us-gaap_CounterpartyNameAxis
= pirs_GovernmentGrantMember
$ 2,430,358us-gaap_Revenues
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueNetMember
/ us-gaap_ConcentrationRiskByTypeAxis
= pirs_RevenueFromPartnersMember
/ us-gaap_CounterpartyNameAxis
= pirs_GovernmentGrantMember